Zydus Lifesciences Q2 results: Net profit falls 26.6% to ₹925.5 crore
Zydus Lifesciences set out an expansion in a quarterly results development.
· BS Companies
Zydus Lifesciences on Wednesday posted a 26.6 per cent decline in consolidated net profit to Rs 925.5 crore in the September quarter weighed down by an increase in expenses. The company had posted a net profit of Rs 1,260.9 crore in the corresponding period of the previous fiscal year, it said in a regulatory filing to the exchanges.
The analysis
Zydus Lifesciences reported ₹925.5 crore, Rs 1,260.9 crore and Rs 7,909.6 crore, with movement of 83%, 18% and 21% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is -4.2% on the day at ₹1,188.10, and has returned +5.1% over three months. It sits 5% below its 52-week high. The pharma & healthcare sector has moved +1.0% over the same period, so Zydus Lifesciences is running 4.1 points ahead of its peers.
For Zydus Lifesciences, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Zydus Lifesciences (ZYDUSLIFE), in Pharma & Healthcare.
- Over three months: Zydus Lifesciences +5.1% against Pharma & Healthcare +1.0% (4.1 points ahead).
- Trading well above normal today: Zydus Lifesciences at 3.2 times its 20-day average volume.
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Zydus LifesciencesZYDUSLIFE · Pharma & Healthcare | ₹1,188.10 | -4.2% | +3.7% | +5.1% | -4.6% | 3.2× | — |
Pharma & Healthcare
1M +2.6% · 3M +1.0%
Zydus Lifesciences
Prices as of 4 Nov 2026, 15:45 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Alembic Pharma shares hit 20% upper circuit after 81% YoY rise in Q2 PAT
Lupin Q2 results: Net profit falls 22% to ₹1,155 cr, revenue at ₹7,827 cr
Stocks in news: ITC, Marico, SBI, Yatra Online, NSE, Container Corp and Sun Pharma
Q2 Results Live: Pfizer's One-Time Gain Lifts Profit; SBI Asset Quality Improves; Solar Industries Profit Zooms 79%
Emcure Pharma shares jump 7% after Q2 profit rises 29% YoY to Rs 325 crore